Form 4: MYGN CEO Samraat Raha Reports Significant RSU Grant

Myriad Genetics CEO Samraat Raha reported the acquisition of 618,557 restricted stock units and subsequent tax-related dispositions.

Summary

• Samraat S. Raha, President and CEO of Myriad Genetics Inc. (MYGN), acquired 618,557 shares of common stock on March 12, 2026, through a grant of time-based restricted stock units (RSUs).
• These RSUs were granted under the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan and vest in three equal annual installments starting one year from the grant date.
• Following the RSU grant, Raha's beneficial ownership increased to 1,111,661 shares.
• On March 13, 2026, 36,304 shares were disposed of at $4.66 per share to satisfy tax withholding obligations related to RSU vesting, reducing beneficial ownership to 1,075,357 shares.
• An additional 10,816 shares were disposed of on March 14, 2026, also at $4.66 per share, for tax withholding, bringing the total beneficial ownership to 1,064,541 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with long-term company performance, despite the routine tax-related share dispositions.

Positives

• The grant of 618,557 restricted stock units to the President and CEO aligns management's interests with long-term shareholder value.
• The RSU grant demonstrates continued commitment to the company's equity incentive plan for key personnel.

Negatives

• The disposition of 47,120 shares (36,304 + 10,816) for tax withholding purposes represents a reduction in direct beneficial ownership, although this is a standard practice for RSU vesting.

Future Outlook

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date, indicating a future vesting schedule for a portion of the CEO's compensation.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units, are a common compensation mechanism in the biotechnology and diagnostics industry to incentivize long-term performance and retain key executives. This grant to Myriad Genetics' CEO is consistent with typical executive compensation structures in the sector.

Comparison to Industry Standards

• The use of time-based restricted stock units (RSUs) for executive compensation is a standard practice across the biotechnology and healthcare sectors, comparable to practices at companies like Illumina (ILMN) or Exact Sciences (EXAS), which frequently utilize similar equity incentive plans to align executive interests with shareholder value.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is also a routine and expected event, mirroring practices observed in executive compensation at most publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's long-term financial interests with shareholder value creation, potentially fostering sustained performance.
• Employees: The use of an equity incentive plan for the CEO may signal the company's broader commitment to performance-based compensation, potentially impacting employee morale and retention strategies.

Next Steps

• The granted restricted stock units will vest in three equal annual installments, starting on March 12, 2027.

Key Dates

Recommendation

The Form 4 filing details routine executive compensation in the form of restricted stock units and subsequent tax-related share dispositions. These transactions are standard and do not provide new fundamental information that would warrant a change in investment recommendation. The grant aligns management incentives, which is generally positive, but the overall impact on the company's valuation or strategic direction is neutral in the short term.

Keywords

Myriad Genetics, MYGN, Samraat Raha, Restricted Stock Units, RSU, Insider Trading, SEC Form 4, Equity Incentive Plan, CEO Compensation, Stock Grant